X Bioscience PCL Income Statement

Financials in millions THB. Fiscal year is January - December.

Millions THB. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	129.65	319.24	311.77	344.49	254.04
Revenue Growth (YoY)	-59.39%	2.40%	-9.50%	35.60%	-38.88%
Cost of Revenue	76.61	180.63	159.67	172.3	126.82
Gross Profit	53.04	138.61	152.11	172.18	127.23
Selling, General & Admin	507.35	389.82	272.53	455.41	227.79
Operating Expenses	507.35	389.82	272.53	455.41	227.79
Operating Income	-454.31	-251.21	-120.43	-283.23	-100.56
Interest Expense	-26.22	-34.29	-39.94	-56.52	-14.45
Interest & Investment Income	-	-	-	-	0.01
Other Non Operating Income (Expenses)	6.26	7.58	11.72	3.33	9.45
EBT Excluding Unusual Items	-474.26	-277.92	-148.65	-336.41	-105.55
Gain (Loss) on Sale of Assets	18.53	-	-	-	-
Pretax Income	-455.74	-277.92	-148.65	-336.41	-105.55
Income Tax Expense	-3.25	-15.84	-1.13	-5.65	-5.65
Earnings From Continuing Operations	-452.49	-262.07	-147.52	-330.77	-99.9
Earnings From Discontinued Operations	-16.94	-	-	-245.22	-176.55
Net Income to Company	-469.43	-262.07	-147.52	-575.99	-276.45
Minority Interest in Earnings	0.57	1.85	-	-	-
Net Income	-468.87	-260.22	-147.52	-575.99	-276.45
Net Income to Common	-468.87	-260.22	-147.52	-575.99	-276.45
Shares Outstanding (Basic)	402	184	125	116	116
Shares Outstanding (Diluted)	402	184	125	116	116
Shares Change (YoY)	118.20%	46.88%	7.78%	-	19.79%
EPS (Basic)	-1.17	-1.41	-1.18	-4.95	-2.38
EPS (Diluted)	-1.17	-1.41	-1.18	-4.95	-2.38
Free Cash Flow	-78.88	-54.84	-133.59	-291.22	-212.57
Free Cash Flow Per Share	-0.20	-0.30	-1.07	-2.50	-1.83
Gross Margin	40.91%	43.42%	48.79%	49.98%	50.08%
Operating Margin	-350.40%	-78.69%	-38.63%	-82.22%	-39.58%
Profit Margin	-361.63%	-81.51%	-47.32%	-167.20%	-108.82%
Free Cash Flow Margin	-60.84%	-17.18%	-42.85%	-84.54%	-83.67%
EBITDA	-436.4	-224.53	-102.69	-189.44	-13.51
EBITDA Margin	-	-70.33%	-32.94%	-54.99%	-5.32%
D&A For EBITDA	17.9	26.68	17.73	93.79	87.05
EBIT	-454.31	-251.21	-120.43	-283.23	-100.56
EBIT Margin	-	-78.69%	-38.63%	-82.22%	-39.58%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.